News archive
Showing 759 results
February 2026
-
Media Release
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite to serve patients in Southern US and add network capacity as RLT expands… -
Story Discovery
The Power of PRECISION: Using AI to Navigate the Future of Prostate Cancer Care
How a Novartis data platform is turning real-world evidence into actionable insights for urologists and oncologists.
-
Media Release
New real‑world data reinforce earlier use of Pluvicto® before chemotherapy in metastatic castration-resistant prostate cancer
In the real-world, Pluvicto® showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC Real‑world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI… -
Media Release
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase II data evaluating safety and efficacy results of remibrutinib for treatment… -
Story Discovery
What's next in Neuroscience drug discovery: A conversation with Genetic Medicine head Bryan Laffitte
A Q&A with Bryan Laffitte, who leads a Novartis team that’s using the tools of genetic medicine to innovate new therapies for neuromuscular and neurodegenerative conditions.
-
Media Release
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1 Remibrutinib, a highly selective oral BTK inhibitor, was well-… -
Media Release
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1 Results favored Vanrafia across multiple… -
Story
Victor Bultó and Thierry Diagana named to 2026 TIME100 Health List
Novartis is proud to share that TIME has recognized Victor Bultó and Thierry Diagana among the most influential people shaping the future of health. Learn more about what drives our honorees.
-
Media Release
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and Basel,…
January 2026
-
Media Release
NFL Greats and Novartis Tackle Prostate Cancer Myths at Super Bowl LX: "Relax, It's a Blood Test"
NFL Icons Coach Bruce Arians, Rob Gronkowski, George Kittle and more partner with Novartis to prioritize early prostate cancer detection One in eight men will face prostate cancer1, yet… -
Story Medicines
Building for the Future: Novartis Expands Manufacturing Hub in North Carolina
The creation of a 700,000-square-foot flagship manufacturing hub marks the continuation of our investment in the US, enabling us to more reliably reach patients across the country.
-
Media Release
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1 Distinction expedites development and review of treatments for serious…